President Trump to Announce Findings on Autism and Prenatal Acetaminophen Use

President Donald Trump is scheduled to announce findings on Monday that suggest a link between prenatal use of acetaminophen, commonly known as Tylenol, and the development of autism spectrum disorders in children. This announcement is expected to be made during an event at the White House, where Trump will be joined by Health Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz.

The anticipated announcement has sparked controversy within the medical community. Kenvue, the manufacturer of Tylenol, has stated, "We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers."

Health experts have also expressed skepticism regarding the proposed link. Dr. Peter Hotez, a pediatrician and co-director of the Center for Vaccine Development at Texas Children's Hospital, commented, "To focus an entire press conference just on Tylenol would be reckless in my opinion without additional info."

Recent studies have explored the association between acetaminophen use during pregnancy and neurodevelopmental disorders. A 2024 study published in JAMA, which analyzed over 2 million children born in Sweden, found no significant association between prenatal acetaminophen exposure and increased risk of autism or ADHD.

The Centers for Disease Control and Prevention (CDC) reports that autism diagnoses in the United States have risen significantly, with rates among 8-year-olds increasing from 0.66% in 2000 to 2.77% in 2020. Experts attribute this increase to improved diagnostic criteria and better screening practices.

The upcoming announcement is expected to reignite debates over the causes of autism and the safety of common medications during pregnancy.